Skip to main content

Advertisement

SpringerLink
Log in

Dyslipidemia in patients with chronic kidney disease

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Institution of Diabetes and Digestive and Kidney Diseases. Kidney disease statistic for the US. https://www.niddk.nih.gov/. Accessed 08 Aug 2016.

  2. Reiss AB, Voloshyna I, De Leon J, Miyawaki N, Mattana J. Cholesterol metabolism in CKD. Am J Kidney Dis. 2015;66(6):1071–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 2016;165(7):473–81.

    Article  PubMed  Google Scholar 

  4. Tannock L. Dyslipidemia in Chronic Kidney Disease. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM et al., editors. Endotext. South Dartmouth (MA): 2000.

  5. Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31(1–3):189–96.

    Article  CAS  PubMed  Google Scholar 

  6. Mittalhenkle A, Stehman-Breen CO, Shlipak MG, Fried LF, Katz R, Young BA, et al. Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. Clin J Am Soc Nephrol. 2008;3(2):450–6.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Matsushita K, Ballew SH, Coresh J. Cardiovascular risk prediction in people with chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(6):518–23.

    Article  PubMed  Google Scholar 

  8. Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Phys. 1997;273(6 Pt 2):F925–30.

    CAS  Google Scholar 

  9. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50(6):1928–35.

    Article  CAS  PubMed  Google Scholar 

  10. Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T, Okada K, et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int. 2003;63(6):2171–7.

    Article  CAS  PubMed  Google Scholar 

  11. Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int Suppl. 1999;71:S227–8.

    Article  CAS  PubMed  Google Scholar 

  12. Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, et al. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25(12):2615–22.

    Article  CAS  PubMed  Google Scholar 

  13. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria. Atherosclerosis. 2001;157(1):211–20.

    Article  CAS  PubMed  Google Scholar 

  14. Vaziri ND, Sato T, Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int. 2003;63(5):1756–63.

    Article  CAS  PubMed  Google Scholar 

  15. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis. 2000;153(2):263–72.

    Article  CAS  PubMed  Google Scholar 

  16. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19(1):73–7.

    Article  CAS  PubMed  Google Scholar 

  17. Vaziri ND, Deng G, Liang K, Hepatic HDL. Receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14(6):1462–6.

    Article  CAS  PubMed  Google Scholar 

  18. Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59(6):2192–6.

    Article  CAS  PubMed  Google Scholar 

  19. Kalra OP, Khaira A, Gambhir JK, Agarwal S, Bhargava SK. Lipoprotein (a) in chronic renal failure: effect of maintenance hemodialysis. Hemodial Int. 2003;7(4):326–31.

    Article  PubMed  Google Scholar 

  20. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res. 1997;38(9):1755–63.

    CAS  PubMed  Google Scholar 

  21. Reblin T, Donarski N, Fineder L, Brasen JH, Dieplinger H, Thaiss F, et al. Renal handling of human apolipoprotein(a) and its fragments in the rat. Am J Kidney Dis. 2001;38(3):619–30.

    Article  CAS  PubMed  Google Scholar 

  22. Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, et al. Vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007;71(10):1036–43.

    Article  CAS  PubMed  Google Scholar 

  23. Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005;46(12):2681–91.

    Article  CAS  PubMed  Google Scholar 

  24. Kidney Disease Improving Global Outcomes. http://kdigo.org/home/. Accessed 08 Aug 2016.

  25. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015;9(2):129–69.

    Article  PubMed  Google Scholar 

  26. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian cardiovascular society guidelines for the Management of Dyslipidemia for the prevention of cardiovascular disease in the adult. The Canadian journal of cardiology. 2016;32(11):1263–82.

    Article  PubMed  Google Scholar 

  27. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int. 2002;22(2):220–8.

    CAS  PubMed  Google Scholar 

  28. Piperi C, Kalofoutis C, Tzivras M, Troupis T, Skenderis A, Kalofoutis A. Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients. Mol Cell Biochem. 2004;265(1–2):57–61.

    Article  CAS  PubMed  Google Scholar 

  29. Rathi TK, Dhrolia MF, Imtiaz S. More hostile dyslipidaemia in chronic kidney disease patients on maintenance haemodialysis than on conservative management. J Pak Med Assoc. 2016;66(8):928–31.

    PubMed  Google Scholar 

  30. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol. 1995;5(9):1703–8.

    CAS  PubMed  Google Scholar 

  31. Jung K, Scheifler A, Schulze BD, Scholz M. Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate. Am J Kidney Dis. 1995;25(4):584–8.

    Article  CAS  PubMed  Google Scholar 

  32. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18(1):293–303.

    Article  CAS  PubMed  Google Scholar 

  33. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–30.

    Article  CAS  PubMed  Google Scholar 

  34. Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation. 1992;54(5):868–71.

    Article  CAS  PubMed  Google Scholar 

  35. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991;18(3):353–8.

    Article  CAS  PubMed  Google Scholar 

  36. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 1994;57(10):1479–83.

    Article  CAS  PubMed  Google Scholar 

  37. Kronenberg F, Konig P, Lhotta K, Ofner D, Sandholzer C, Margreiter R, et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb. 1994;14(9):1399–404.

    Article  CAS  PubMed  Google Scholar 

  38. Mak RH. Effect of metabolic acidosis on hyperlipidemia in uremia. Pediatr Nephrol. 1999;13(9):891–3.

    Article  CAS  PubMed  Google Scholar 

  39. Perez-Granados AM, Navas-Carretero S, Schoppen S, Vaquero MP. Reduction in cardiovascular risk by sodium-bicarbonated mineral water in moderately hypercholesterolemic young adults. J Nutr Biochem. 2010;21(10):948–53.

    Article  CAS  PubMed  Google Scholar 

  40. Allegra V, Martimbianco L, Vasile A. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant. 1997;12(5):924–32.

    Article  CAS  PubMed  Google Scholar 

  41. Pollock CA, Wyndham R, Collett PV, Elder G, Field MJ, Kalowski S, et al. Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int. 1994;45(3):897–902.

    Article  CAS  PubMed  Google Scholar 

  42. Alnahal AA, Tahan M, Fathy A, Fathy T. Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. Saudi J Kidney Dis Transpl. 2014;25(4):808–13.

    Article  PubMed  Google Scholar 

  43. Wang Y, Lu H, Huang Z, Lin H, Lei Z, Chen X, et al. Apolipoprotein E-knockout mice on high-fat diet show autoimmune injury on kidney and aorta. Biochem Biophys Res Commun. 2014;450(1):788–93.

    Article  CAS  PubMed  Google Scholar 

  44. Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol. 1997;79(5A):24–8.

    Article  CAS  PubMed  Google Scholar 

  45. Chertow GM, Burke SK, Raggi P. Treat to goal working G. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245–52.

    Article  CAS  PubMed  Google Scholar 

  46. Shantouf R, Budoff MJ, Ahmadi N, Tiano J, Flores F, Kalantar-Zadeh K. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol. 2008;28(2):275–9.

    Article  CAS  PubMed  Google Scholar 

  47. Katopodis KP, Andrikos EK, Gouva CD, Bairaktari ET, Nikolopoulos PM, Takouli LK, et al. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int. 2006;26(3):320–7.

    CAS  PubMed  Google Scholar 

  48. Khajehdehi P, Taheri S. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. J Ren Nutr. 2003;13(2):78–83.

    Article  PubMed  Google Scholar 

  49. Wehmeier K, Beers A, Haas MJ, Wong NC, Steinmeyer A, Zugel U, et al. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta. 2005;1737(1):16–26.

    Article  CAS  PubMed  Google Scholar 

  50. Shapiro MD, Fazio S. From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ Res. 2016;118(4):732–49.

    Article  CAS  PubMed  Google Scholar 

  51. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–8.

    Article  CAS  PubMed  Google Scholar 

  52. Morita T, Morimoto S, Nakano C, Kubo R, Okuno Y, Seo M, et al. Renal and vascular protective effects of ezetimibe in chronic kidney disease. Intern Med. 2014;53(4):307–14.

    Article  PubMed  Google Scholar 

  53. He YM, Feng L, Huo DM, Yang ZH, Liao YH. Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. Int Urol Nephrol. 2014;46(2):433–42.

    Article  CAS  PubMed  Google Scholar 

  54. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34(7):642–50.

    Article  CAS  PubMed  Google Scholar 

  55. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.

    Article  PubMed  Google Scholar 

  56. Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.

    Article  Google Scholar 

  57. Highlights of Prescribing Information (database on the Internet). Available from http://www.rxabbvie.com/pdf/niaspan.pdf. Accessed 18 Aug 2016.

  58. Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol. 2012;11:140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088–93.

    Article  CAS  PubMed  Google Scholar 

  60. Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60(20):2061–71.

    Article  CAS  PubMed  Google Scholar 

  61. Davis TM, Ting R. Best JD, Donoghoe MW, Drury PL, Sullivan DR et al. effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetologia. 2011;54(2):280–90.

    Article  CAS  PubMed  Google Scholar 

  62. Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136(1):4–16.

    Article  PubMed  Google Scholar 

  63. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006;189(1):19–30.

    Article  CAS  PubMed  Google Scholar 

  64. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024–33.

    Article  CAS  PubMed  Google Scholar 

  65. Lauretani F, Maggio M, Pizzarelli F, Michelassi S, Ruggiero C, Ceda GP, et al. Omega-3 and renal function in older adults. Curr Pharm Des. 2009;15(36):4149–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: a review. Clin Ther. 2015;37(10):2153–79.

    Article  CAS  PubMed  Google Scholar 

  67. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.

    Article  PubMed  Google Scholar 

  68. KDOQI. KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. http://www2.kidney.org/professional/kdoqi/guidelines_lipids/iii.htm. Accessed 30 Aug 2016.

  69. Page MM. Watts GF. PCSK9 inhibitors - mechanisms of action. Aust Prescr. 2016;39(5):164–7.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom heart and renal protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473–84.

    Article  CAS  PubMed  Google Scholar 

  71. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, et al. The second United Kingdom heart and renal protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47(3):385–95.

    Article  CAS  PubMed  Google Scholar 

  72. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.

    Article  CAS  PubMed  Google Scholar 

  74. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–407.

    Article  CAS  PubMed  Google Scholar 

  75. Holdaas H, Fellstrom B, Holme I, Nyberg G, Fauchald P, Jardine A, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (assessment of Lescol in renal transplantation) study design and baseline data. J Cardiovasc Risk. 2001;8(2):63–71.

    Article  CAS  PubMed  Google Scholar 

  76. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This review was supported by grants from the National Institutes of Health RR021954 and Veterans Affairs CX000975.

Author information

Authors and Affiliations

  1. Department of Internal Medicine University of Kentucky, Lexington, KY, USA

    Matthew R. Hager

  2. Division of Endocrinology and Molecular Medicine, University of Kentucky, Lexington, KY, USA

    Archana D. Narla & Lisa R. Tannock

  3. Department of Veterans Affairs, Lexington, KY, USA

    Lisa R. Tannock

  4. University of Kentucky, 900 S. Limestone, Room 553 CTW, Lexington, KY, 40536-0200, USA

    Lisa R. Tannock

Authors
  1. Matthew R. Hager
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Archana D. Narla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa R. Tannock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa R. Tannock.

Ethics declarations

Conflict of interest

The authors have nothing to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hager, M.R., Narla, A.D. & Tannock, L.R. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord 18, 29–40 (2017). https://doi.org/10.1007/s11154-016-9402-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-016-9402-z

Keywords

Search

Navigation